Harbour BioMed raises $50M, acquires Harbour Antibodies

Harbour BioMed (Shanghai, China) closed a $50 million series A round and acquired antibody company Harbour Antibodies B.V. (Rotterdam, the Netherlands). The acquisition includes both cash and equity components.

Harbour BioMed CEO Jingsong Wang told BioCentury the company was launched this year with the series A investment from Advantech Capital, Legend Capital, and its founders, to fund both the acquisition and Harbour BioMed's product development. Wang declined to disclose details of the company's pipeline, but said it is developing therapeutic antibodies in oncology...